GORE-TEX® Stretch Vascular Graft: What Patients Should Know About Long-Term Calcification

Published by Justpoint Inc.

If you have a GORE-TEX® Stretch Vascular Graft — a synthetic blood-vessel replacement implanted during peripheral bypass surgery, dialysis-access surgery, aortic surgery, or trauma repair — long-term safety data point to a specific concern: the ePTFE graft material has been associated with dystrophic calcification (Lejay et al., 2023; Turner et al., 2024). Calcium may gradually deposit inside the ePTFE (expanded polytetrafluoroethylene) walls of the graft, potentially making it stiffer and less elastic over time. That stiffening has been linked to reduced blood flow, clot formation, and graft failure.

This article explains what the device is, what the published evidence shows about calcification risk, how the synthetic graft compares to newer tissue-engineered alternatives, what symptoms to watch for, and how to verify whether you have this specific implant.

What the GORE-TEX® Stretch Vascular Graft is

The GORE-TEX® Stretch Vascular Graft is a synthetic prosthesis made of expanded polytetrafluoroethylene (ePTFE). It was cleared by the U.S. Food and Drug Administration through the 510(k) pathway on December 6, 1990, under premarket notification number K903931. The manufacturer is W. L. Gore & Associates, Inc., headquartered in Flagstaff, Arizona.

The FDA classifies the device as Class II (“Prosthesis, Vascular Graft, of 6mm and Greater Diameter”) under product code DSY, regulation 21 CFR 870.3450. Class II is a moderate-risk classification, meaning the device is subject to special controls but did not require a full premarket approval (PMA) trial — the manufacturer only had to demonstrate “substantial equivalence” to a previously cleared graft.

The Stretch line is sold in several configurations:

• Straight grafts — the most common form, for direct vessel replacement or bypass
• Tapered grafts — for sites where vessel diameter changes
• Removable-ring grafts — for areas where the graft must resist external compression
• Bifurcated grafts — Y-shaped, for aortic procedures

According to the manufacturer’s labeling, the device is indicated for replacement or bypass of diseased vessels in patients with occlusive or aneurysmal disease, for trauma patients requiring vascular replacement, for dialysis access, and for other vascular procedures.

The calcification problem, in plain language

Dystrophic calcification means that calcium minerals — the same ones that make bones and teeth hard — can deposit inside the porous walls of the graft material. It is “dystrophic” because the calcium accumulates in damaged or non-living tissue, not in healthy bone. Over time, the graft may become stiffer and lose the flexibility it had when it was first implanted.

When a vascular graft loses flexibility, three things can go wrong:

1. Reduced compliance — a stiffer graft may not expand and contract with each heartbeat the way a healthy artery does. This mechanical mismatch may put stress on the graft and the surrounding tissue.
2. Thrombotic occlusion — a blood clot can form on the stiffer, irregular surface, blocking blood flow through the graft.
3. Graft failure — over enough time, the structural changes can lead to outright failure of the graft, requiring re-operation.

This is not a new finding. The medical literature has documented synthetic graft calcification for more than three decades.

What the published evidence shows

Two recent peer-reviewed publications provide the clearest picture of the calcification risk for ePTFE grafts.

Systematic review of reported cases (Lejay et al., 2023). A systematic review published in the European Journal of Vascular and Endovascular Surgery — Vascular Forum compiled all published cases of synthetic vascular graft calcification over a 35-year period. The authors identified 90 cases in total: 73 cases of ePTFE graft calcification and 17 cases involving polyester (PET / Dacron) grafts. The review noted that most ePTFE calcification cases were “unexpectedly noted in grafts used during cardiovascular procedures and subsequently removed” — meaning the calcification often was not discovered until the graft was explanted for other reasons. Because this is an aggregation of published case reports, the figures reflect cases that came to publication and cannot establish how common calcification is across the implanted population — case-series reviews are subject to reporting bias and selection bias.

Head-to-head comparison with tissue-engineered grafts (Turner et al., 2024; DOI 10.1038/s41467-024-46431-4). A study published in Nature Communications compared ePTFE grafts against tissue-engineered vascular grafts (TEVGs) in both a sheep model and a matched human cohort. Using CT-based measurements, the researchers found that ePTFE grafts accumulated an average calcium burden score of 269 HU·cm³ (a CT-derived measure combining calcium density with volume), compared with 0.1 HU·cm³ in tissue-engineered grafts — the TEVG value is near the limit of CT detection. ePTFE calcification showed “early onset (within months) and late rapid progression.” Both the animal and clinical results were statistically significant (p < 0.001 in humans, p < 0.0001 in sheep). A matched-cohort comparison of this kind establishes association rather than causation; factors not captured in the analysis (patient selection, surgical indication, length of follow-up) may contribute to the observed difference.

The combined picture: dystrophic calcification of ePTFE is well-described in the published literature (Lejay 2023; Turner 2024), appears to accumulate faster and more heavily than in newer tissue-engineered alternatives, and may begin within months of implantation even though clinical symptoms may take years to appear.

Who may be most affected

The published reports do not single out a specific patient demographic or anatomical site as carrying the highest risk. However, the underlying mechanism suggests that length of time in the body matters most: the longer the graft has been implanted, the more time calcium has had to deposit and accumulate. Patients whose grafts were placed many years ago — especially in cardiovascular or peripheral arterial positions — may be more likely to be affected than those with recent implants.

Warning signs to monitor

Calcification is gradual and often silent in its early stages. When it becomes clinically significant, it typically presents through the consequences of reduced blood flow or graft obstruction. Watch for:

• New or worsening pain in the limb or area supplied by the graft, especially with walking or exertion
• Changes in skin color or temperature — paleness, coolness, or bluish discoloration in the affected limb
• Weakened or absent pulses below the graft site
• Swelling, redness, or tenderness along the path of the graft
• For dialysis-access grafts: reduced flow during dialysis, clotting episodes, or difficulty cannulating the graft
• For aortic or visceral grafts: new abdominal pain, back pain, or changes in bowel or kidney function

These symptoms can also indicate other vascular problems unrelated to the graft. While these are common symptoms associated with graft complications, any symptoms or concerns should be discussed with your healthcare provider so they can determine the cause and appropriate next steps rather than relying on self-diagnosis.

How to confirm you have this specific device

If you are unsure which graft you have, your healthcare provider can help identify your implant using one of the following methods:

1. Your operative report. Hospitals are required to keep the operative report from your surgery. It will list the device manufacturer (W. L. Gore & Associates), the model name (GORE-TEX® Stretch Vascular Graft), and a lot or catalog number. You can request a copy through your hospital’s medical records department.
2. Your implant card or patient booklet. Many vascular surgeons give patients a card or booklet identifying the implanted device. If you kept the paperwork from your surgery, the device should be listed there.
3. Your surgeon’s office. Your vascular surgeon’s office maintains records of the devices used in each procedure. A call or patient-portal message asking specifically “What graft was used in my [date] surgery — manufacturer, model, and catalog number?” is usually sufficient.

If you confirm you have a GORE-TEX® Stretch Vascular Graft, share that information with your healthcare provider (HCP) or any clinician responsible for your long-term cardiovascular care.

What to do — questions for your doctor

If you have this graft, consider asking your vascular specialist:

• How long has my graft been in place, and what is the typical surveillance interval recommended for it?
• Are there imaging studies (duplex ultrasound, CT angiography) that would tell us whether calcification is developing?
• Are my current symptoms (if any) consistent with graft calcification or with something else?
• If the graft eventually has to be replaced, what are the surgical options, including newer tissue-engineered alternatives?

Reporting a problem to the FDA

If you or a family member believe you have experienced harm from a vascular graft, you can report the event yourself to the FDA’s MedWatch program. Reports from patients and caregivers add to the data the FDA uses to monitor device safety:

• Online: www.fda.gov/medwatch
• Phone: 1-800-FDA-1088 (1-800-332-1088)

Filing a MedWatch report does not initiate a legal claim and is not a substitute for medical care, but it does help the FDA detect safety patterns. Your treating clinician can also file a report on your behalf.

Regulatory and legal context

As of this writing, there is no FDA recall or Warning Letter specifically directed at the GORE-TEX® Stretch Vascular Graft for calcification. The device remains in commercial distribution. The published evidence on ePTFE calcification — the 73 reported cases in Lejay 2023 and the head-to-head density comparison in Turner 2024 — has been described as a recognized material limitation of ePTFE rather than a manufacturing defect.

Whether and how patients with long-implanted ePTFE grafts should be monitored is an active question among vascular specialists.

Check if you qualify

---

Contact Us

[email protected]

---

Related articles

If you are researching this device, these related Justpoint patient guides may also be relevant:

• Endotak Lead System: ePTFE Calcification, the 2025 Recall, and What Patients Should Know — Implantable defibrillator leads with the same ePTFE-calcification material failure

Sources and how to verify

• FDA 510(k) record for K903931 — searchable in the FDA Premarket Notification Database at accessdata.fda.gov. Lists W. L. Gore & Associates, Inc. as applicant; decision date December 6, 1990; product code DSY; regulation 21 CFR 870.3450; classification “Prosthesis, Vascular Graft, of 6mm and Greater Diameter.”
• Lejay A, Bratu B, Kuntz S, Neumann N, Heim F, Chakfé N. “Calcification of Synthetic Vascular Grafts: A Systematic Review.” EJVES Vasc Forum. 2023. PubMed: https://pubmed.ncbi.nlm.nih.gov/37416860/. Reports 73 cases of ePTFE graft calcification (and 17 PET cases) over a 35-year review period.
• Turner ME, Blum KM, Watanabe T, Schwarz EL, Nabavinia M, et al. “Tissue engineered vascular grafts are resistant to the formation of dystrophic calcification.” Nature Communications 15:2187 (2024). DOI: https://doi.org/10.1038/s41467-024-46431-4. PubMed: https://pubmed.ncbi.nlm.nih.gov/38467617/. Reports a calcium burden score of 269 HU·cm³ for PTFE grafts versus 0.1 HU·cm³ (near detection limit) for tissue-engineered vascular grafts.
• Manufacturer information: W. L. Gore & Associates, Inc., Flagstaff, Arizona. Customer support: +1 (928) 864-2927. Patient-facing Instructions for Use are available at eifu.goremedical.com.
• FDA MedWatch (adverse-event reporting): www.fda.gov/medwatch or 1-800-FDA-1088.

This article was published by Justpoint Inc. The information provided is for educational purposes, does not constitute medical or legal advice and is based on publicly available research and regulatory communications. Findings may vary depending on individual circumstances, device type, and clinical context. If you have a medical device that may be affected, please consult your physician. If you believe you may have a legal claim, please consult a qualified attorney.

Justpoint Inc. supports Justpoint Law (Justpoint PLLC) by providing operational and administrative services. All legal services are provided by Justpoint Law, and any client-related communications are made on its behalf.